PROSTATE is a premier, peer-reviewed journal published by Wiley, focusing on the critical fields of urology and oncology. With an established history since 1980 and a projected convergence through 2024, this influential journal serves as a vital resource for researchers, clinicians, and students alike. It holds a prestigious position in the academic landscape, classified in the Q1 category for Urology and Q2 in Oncology as of 2023, demonstrating its significant contribution to these disciplines. With a Scopus rank of #23 in Urology and #169 in Oncology, PROSTATE is pivotal for advancing knowledge and fostering innovation in prostate research, treatment, and overall male health. The journal aims to publish high-quality original articles, reviews, and clinical studies that address the complexities of prostate-related conditions, ultimately seeking to improve patient outcomes and propagate best practices in the medical community.

DIAGNOSTIC CYTOPATHOLOGY is a scholarly journal dedicated to advancing the field of cytopathology through the publication of high-quality research and reviews. Founded in 1985 and published by Wiley, this journal provides vital insights into the diagnosis and management of diseases through cytological techniques. With a strong presence in the academic community, it currently holds a Q3 ranking in the fields of Histology, Medicine (miscellaneous), and Pathology and Forensic Medicine, reflecting its commitment to fostering knowledge and innovation in these areas. Researchers and clinicians alike can benefit from its comprehensive articles that delve into cutting-edge methodologies and diagnostic strategies. Although not an Open Access journal, DIAGNOSTIC CYTOPATHOLOGY remains a crucial resource for professionals seeking to enhance their understanding and practice in the diagnostic realm. With an ISSN of 8755-1039 and an E-ISSN of 1097-0339, the journal continues to publish impactful studies well into 2024, ensuring that essential advancements in cytopathology reach a global audience.

The Journal of Cancer Research and Therapeutics is a prominent peer-reviewed platform dedicated to advancing scientific knowledge in the fields of oncology, radiology, and therapeutic interventions. Published by Wolters Kluwer Medknow Publications in India, this journal has been an essential resource for researchers and professionals since its inception in 2005, with a convergence of findings through to 2024. Although classified within the Q3 quartile across multiple relevant categories in the 2023 rankings, the journal maintains a significant impact in the fields of medicine, particularly in oncology and radiology, as evidenced by its Scopus rankings. The journal aims to disseminate high-quality research, case studies, and clinical trials that contribute to understanding and improving cancer treatments and patient care. With its accessibility to a global audience, the Journal of Cancer Research and Therapeutics plays a pivotal role in fostering dialogue and collaboration among researchers and healthcare professionals dedicated to combating cancer.

Diagnostics is a pioneering open-access journal published by MDPI, catering to the critical field of clinical biochemistry since its establishment in 2011. Based in Switzerland, this esteemed journal, with E-ISSN 2075-4418, has gained significant recognition within the academic community, reflected in its 2023 Scopus rankings placing it in Q2 for Clinical Biochemistry and showcasing its impact in related medical disciplines. With a commitment to disseminating high-quality research that advances the understanding of diagnostic techniques and methodologies, Diagnostics covers a broad spectrum of topics including biochemical markers, diagnostic imaging, and molecular diagnostics. The journal's open access model ensures that groundbreaking findings are readily available to researchers, professionals, and students alike, fostering an environment of knowledge sharing and collaboration. As the field of diagnostics continues to evolve, Diagnostics remains at the forefront, paving the way for innovations that enhance health outcomes globally.

Journal of Cancer is a premier, peer-reviewed academic journal published by IVYSPRING INTERNATIONAL PUBLISHING that focuses on advancing the field of oncology. With an impact factor reflecting its significant contributions, this journal ranks in the 80th percentile of medical journals pertaining to oncology, positioning it at #79 out of 404 in Scopus. Since its inception in 2010, the journal has embraced an Open Access model, ensuring that groundbreaking research reaches a global audience without barriers. Based in Australia, the journal addresses a wide array of topics within cancer research, catering to researchers, healthcare professionals, and students committed to enhancing their understanding of the complexities of cancer. Amidst evolving challenges in oncology, the Journal of Cancer serves as a vital platform for disseminating innovative findings, fostering collaboration, and promoting informed decisions that can lead to improved cancer outcomes worldwide.

World Journal of Gastrointestinal Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a pivotal resource in the evolving fields of gastroenterology and oncology, particularly focused on the intricate relationship between gastrointestinal disorders and cancer. Established in 2014, the journal continues to publish influential research, boasting a commendable Q2 ranking in both the gastroenterology and oncology categories for 2023, which underscores its importance in these critical medical domains. With a diverse range of topics and studies, it serves as an essential platform for researchers, healthcare professionals, and students aiming to stay informed about the latest advancements and innovations in gastrointestinal oncology. Though currently not classified as open access, the journal's rigorous peer-review process ensures the dissemination of high-quality research that significantly contributes to clinical practice and patient care. Its positioning in the Scopus rankings also highlights its competitive standing within the scientific community, fostering discussions that are crucial for advancing both fields. Explore the latest insights and findings to enhance your understanding and contribute to the ongoing dialogue in gastrointestinal health and oncology.

PET Clinics, published by Elsevier Inc, is a premier academic journal focusing on the advancements and applications of Positron Emission Tomography (PET) in various medical fields. With its ISSN 1556-8598 and E-ISSN 1559-7814, the journal has established a strong reputation in the scientific community, reflected in its impressive Q1 quartile rankings in Medicine (miscellaneous), Radiation, and Radiology, Nuclear Medicine, and Imaging for 2023. The journal operates within a well-defined scope that bridges innovative research and practical clinical applications, targeting professionals, researchers, and students keen on the intersection of nuclear medicine and imaging technologies. Although not an open-access journal, PET Clinics ensures accessibility through institutional subscriptions, making valuable insights available to the academic community. With an emphasis on enhancing patient care and treatment outcomes through cutting-edge imaging techniques, this journal serves as an essential resource for those seeking to expand their knowledge and expertise in the rapidly evolving field of PET.

CYTOPATHOLOGY is a pivotal journal published by WILEY, focusing on the dynamic field of cytopathology within the broader medical and pathological sciences. Founded in 1990, this journal has become a crucial resource for researchers, professionals, and students interested in the microscopic examination of cell samples for diagnostic purposes. With an ISSN of 0956-5507 and E-ISSN of 1365-2303, CYTOPATHOLOGY is indexed in Scopus, where it currently holds a rank of #113 in Pathology and Forensic Medicine and #43 in Histology, placing it in the Q3 quartile for multiple categories in 2023. The journal publishes original research, reviews, and clinical studies that advance the understanding and application of cytopathology and its significance in health care. Although not an Open Access journal, its commitment to providing high-quality research makes it an essential platform for disseminating knowledge in the field. Researchers and practitioners looking to stay at the forefront of cytopathology developments will find CYTOPATHOLOGY to be an invaluable resource.

Cancer Medicine is a leading open access journal published by WILEY, focusing on innovative research and advancements in the fields of Cancer Research, Oncology, and Radiology, with an impressive impact evidenced by its 2023 Q2 ranking in Cancer Research and Q1 rankings in both Oncology and Radiology, Nuclear Medicine and Imaging. With an ISSN of 2045-7634, this journal has been committed to disseminating pivotal findings since its inception in 2012, serving as a vital platform for researchers, practitioners, and students alike. The journal proudly embodies the spirit of open access, ensuring that groundbreaking cancer research is accessible to a global audience. Located in the United Kingdom, it spans a wide array of topics, promising comprehensive insights into cancer therapies, molecular mechanisms, and imaging techniques, thereby significantly contributing to the enhancement of cancer care and treatment outcomes. Researchers interested in exploring the latest advancements in cancer medicine will find this journal an indispensable resource.

ONCOLOGY is a prestigious journal published by KARGER, dedicated to advancing the field of cancer research and treatment. Established in 1948, this peer-reviewed journal has established a significant presence in the medical community, reflected by its impressive impact factor and Q2 category rankings in both Cancer Research and Oncology as of 2023. With a focus on groundbreaking research and comprehensive reviews, ONCOLOGY serves as a crucial resource for researchers, clinicians, and students interested in the latest developments in the fight against cancer. Although it currently does not offer open access, the journal's reputation ensures that it reaches a wide audience in academia and clinical practice. Its commitment to excellence is underscored by its consistent rankings in key disciplines, making it a vital publication for anyone involved in cancer research, biology, or associated medical fields. The journal is headquartered in Basel, Switzerland, positioning it at the heart of European medical research.